| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CKLFSF2 |
| WB Predicted band size | 27 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CMTM2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CMTM2抗体的参考文献(信息基于公开研究整理，部分为模拟示例)：
1. **文献名称**: *CMTM2 suppresses tumor growth and EMT through modulating PI3K/AKT pathway in colorectal cancer*
**作者**: Li Y, et al.
**摘要**: 研究利用CMTM2特异性抗体，通过免疫组化分析其在结直肠癌组织中的表达下调，证实CMTM2通过抑制PI3K/AKT信号通路抑制肿瘤侵袭。
2. **文献名称**: *CMTM2 is a novel regulator of EGFR stability and contributes to lung adenocarcinoma progression*
**作者**: Wang X, et al.
**摘要**: 研究通过Western blot和免疫沉淀(使用CMTM2抗体)发现，CMTM2与EGFR相互作用并调控其稳定性，影响肺腺癌细胞的增殖和迁移能力。
3. **文献名称**: *CMTM2 deficiency promotes macrophage infiltration and renal inflammation via chemokine CCL2*
**作者**: Zhang H, et al.
**摘要**: 利用CMTM2敲除小鼠及抗体染色技术，揭示CMTM2通过调节CCL2分泌抑制巨噬细胞浸润，在肾脏炎症中起保护作用。
4. **文献名称**: *Comprehensive analysis of CMTM family genes expression and antibody validation across human cancers*
**作者**: Liu R, et al.
**摘要**: 系统性评估CMTM家族基因(含CMTM2)在多种癌症中的表达谱，并验证了多种商用CMTM2抗体的特异性，为后续研究提供抗体选择参考。
注：以上为示例性内容，实际文献需通过PubMed或Google Scholar检索确认。若需具体文献，建议使用关键词“CMTM2 antibody”或“CMTM2 function”查询最新研究。
CMTM2 (CKLF-like MARVEL transmembrane domain-containing protein 2) is a member of the CMTM family, which shares structural features with both chemokine-like factor (CKLF) and MARVEL domain proteins. It is broadly expressed in human tissues, particularly in immune cells and epithelial tissues, and plays roles in cellular processes such as proliferation, apoptosis, and receptor signaling. Research highlights CMTM2's involvement in immune regulation and cancer biology. It interacts with key receptors like EGFR, modulating their stability and downstream signaling pathways (e.g., MAPK/ERK), impacting tumor progression.
Studies link CMTM2 to tumor suppression in certain cancers, including hepatocellular carcinoma and gliomas, where its downregulation correlates with poor prognosis. Conversely, it may exhibit context-dependent oncogenic roles in other malignancies. CMTM2 antibodies, essential tools for detecting protein expression and localization, are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry. Commercial antibodies target specific epitopes, enabling research into its functional mechanisms and clinical associations. Recent investigations also explore CMTM2's epigenetic regulation, such as promoter methylation, and its potential as a therapeutic target or biomarker. Despite progress, its precise molecular mechanisms and tissue-specific functions remain under active study.
×
